GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...

I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

A team at the University of Calgary is making scientific advances in understanding plant adaptation, which could ultimately be used to find ways to make agricultural crops more resilient to heat ...

Today has seen a lot of movement in Russia's Kursk region, where Ukraine launched an offensive last year. We'll be back tomorrow with more updates on the war in Ukraine. But here is a look at the ...

Trudeau to Resign as Canada’s Prime Minister: ‘It’s Time for a Reset’ Justin Trudeau announced that he was also stepping down as the leader of Canada’s Liberal Party. He will remain in ...

"We are worried we don't get any eggs. What are we going to do?" said Merie Belluomini, co-owner of San Francisco's Victoria Pastry Company. Mark Kotsay sees a new era ahead for the Athletics, and ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...